<DOC>
	<DOCNO>NCT02491242</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety , evolution cause lead change , dual therapy base Dolutegravir patient require change virologically effective antiretroviral therapy .</brief_summary>
	<brief_title>Dolutegravir-based Dual Therapies HIV-infected Patients With Virological Suppression</brief_title>
	<detailed_description>Despite high rate virological suppression low risk toxicity , HIV-infected patient continue need new antiretroviral strategy , dual therapy , different end-organ involvement ( kidney , bone , cardiovascular.. ) , intolerance toxicity . To date , protease inhibitor ( PI ) -based regimen able permit use dual therapy ( two antiretrovirals ) , especially case patient history virological failure regimen . However , recent license Dolutegravir , integrase inhibitor high genetic barrier , could help clinician manage patient intolerance toxicity nucleoside analogues without put risk virological suppression .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Older 18 year Receiving virologically effective antiretroviral regimen Switching dual therapy base dolutegravir intolerance toxicity nucleoside analogues Pregnant woman Receiving investigational drug Recent diagnosis opportunistic infection ( &lt; 1 month )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>dolutegravir</keyword>
	<keyword>intolerance</keyword>
	<keyword>dual therapy</keyword>
</DOC>